In a new case of medication chaos, Granules India has initiated a significant recall of over 33,000 bottles of Metoprolol Succinate in the United States, a move sparking concern over the pharmaceutical industry’s quality control practices.
See the tweet below!
The tablets failed crucial “dissolution specifications,” leading to questions about safety and efficacy.
The recall involves 33,024 bottles of Metoprolol Succinate extended-release tablets distributed across the United States.
Granules India, a Hyderabad-based pharmaceutical giant, identified the manufacturing issue during routine stability testing.
The US Food and Drug Administration (USFDA) issued a Class II recall alert, indicating that while there’s some risk, it’s unlikely to result in serious health consequences.
These stability tests failed specifically due to “failed dissolution specifications,” which ensures a drug’s active ingredients are released correctly.
The issue was uncovered during the sixth month of stability studies, underscoring the importance of consistent quality control checks in pharmaceutical production.
The affected tablets were manufactured in India and distributed by Granules Pharmaceuticals Inc. in the US.
“The USFDA reported that the India-produced lot failed to meet dissolution specifications during stability studies,” The Economic Times reports.
This proactive recall began on June 24, demonstrating Granules India’s commitment to regulatory compliance and medication safety.
This move is crucial, given that the product’s dissolution failure could potentially impact its efficacy.
Despite the recall, patients are advised not to discontinue their medication without consulting a healthcare provider.
Medical professionals emphasize the importance of assessing each patient’s individual needs before making any changes.
“The use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal,” the FDA said.
This situation highlights the ongoing debate around globalization in the pharmaceutical industry.
While outsourcing production to countries like India may reduce costs, it amplifies concerns over quality assurance.
The recall affects tablets in both 100-count and 500-count bottles, distributed nationwide.
The recall’s implications reached financial markets as well, with shares of Granules India trading 0.54% lower on the BSE, reflecting investor unease.
Hyderabad-based Granules recalls over 33,000 bottles of blood lowering medication#Granules #USFDA #Pharmaceutical #drugRecallhttps://t.co/rWkVwuOCQw
— Telangana Today (@TelanganaToday) July 9, 2025
